Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — 9M 2019 Earnings Presentation
30 slides from Pt Prodia Widyahusada Tbk's earnings presentation, October 2019
Slide 1: 9M 2019 Results Update
9M 2019 Results Update October 2019
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Market & Business Highlights 04 Business & Financial Updates 20 Healthcare & Diagnostic Market 05 New Outlets added in 9M 2019 21 Market Share 06 Revenue 22 Esoteric Testing Market 07 Quarterly Revenue 23 Genetic Testing Market 08 No. of Visit and Rev/Visit 24 Services & Customer Seg
Slide 4: Market & Business Highlights
Market & Business Highlights 4
Slide 5: Growing Market for the Healthcare and Diagnostic Lab Sector
Growing Market for the Healthcare and Diagnostic Lab Sector Indonesian Healthcare Market is Growing Indonesia Diagnostic Lab Forecasting Market size by revenue; In USD Billion Market size by revenue; In IDR Trillion 11A-13A 13A-15E 15E-19F 13 15 17 20 22 25 27 CAGR 4.9% CAGR 0.3% CAGR 6.9% 5 5 34 4
Slide 6: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Independent Clinical Labs (2016 & 2017) 38.5% 38.7% 29.2% 2016 29.0% 2017 32.3% 32.3% Source: IQVIA Analysis (2018) Note: Next 5 Players consists of: 1) Kimia Farma, 2) Pramita, 3) Parahita, 4) BioMedika , 5)
Slide 7: Potential Growth for Esoteric & Genetic Testing
Potential Growth for Esoteric & Genetic Testing Esoteric Testing Market Global Statistics Regional Outlook > USD 19 Billion 9.4% Germany China Market US Industry Market CAGR CAGR Share (2017) (2018-2024) (2018-2024) CAGR 2018-2024 Industry Size (2017) 35% 8.5% 12.5% The Esoteric Testing Industry is
Slide 8: Potential Growth for Advanced & Genetic Testing
Potential Growth for Advanced & Genetic Testing Genetic Testing Market Global Statistics Landscape By Application Cancer Diagnosis Cardiovascular Revenue Share Disease Diagnosis (2017) CAGR (‘18-’24) USD 5.6 Billion 12.8% USD 10.6 Billion >11.6% By Testing Type Diagnostic Prenatal and Testing Revenu
Slide 9: Comprehensive Service Offering
Comprehensive Service Offering Targets Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation Predictive, Preventive, General Medical Preventive Treatment Personalized Package Check-Up Services Testing Walk-In Cu
Slide 10: Prodia Laboratories
Prodia Laboratories Indonesian Pioneer in Clinical Laboratory Testing Established Received SMK3 accreditation and OHSAS 2015, along professional with the Award as "Diagnostic Services Company of the management team Year 2015" from Frost & Sullivan 9M 2019 Scholarships given Opened the first green bu
Slide 11: Scalable Hub and Spoke Model
Scalable Hub and Spoke Model Significant Economies of Scale Achieved Prodia Clinical Labs, Centralized information Hospitals and Other Prodia Referral with integrated IT “Hub and spoke” model Clinics may refer tests to Lab Services platform that connects offers scalable platform PRLS (PRLS) each lab
Slide 12: 2018-2019 Awards
2018-2019 Awards WOW Brand Award 2018 & 2019 from Markplus Inc. Indonesia Most Innovative Business Award 2018 from Warta Ekonomi Outstanding Corporate Innovator (OCI) Award 2018 From SWA Corporate Image Award (IMAC) 2018 & 2019 from Frontier Consulting Group & Marketing Magazine Top Brand Award 2018
Slide 13: Senior Leadership and Management Team
Senior Leadership and Management Team Experienced, Professional Management Team with a Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 46 Experience 46 Experience 36 Experience 30 Experience 32 Experience Andi Gunawan Endang Scott Andrew Lukas S
Slide 14: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 15: Growth Strategy
Growth Strategy 15
Slide 16: Growth Strategy
Growth Strategy A Near-term B Long-term Expand our presence and grow Focus on the development of next- our network of outlets in both generation diagnostic existing and new markets in technologies for precision medicine Indonesia Upgrade existing clinical laboratories to provide wider range of tests
Slide 17: Near Term Growth Plan
Near Term Growth Plan Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 Expand Network Upgrade Clinical Enhance Operating Focus on of Outlets Labs Efficiency Quality 31 regional referral labs Upgrade up to 39 clinical labs to PHC3 Clinics Up to 33 additional clinical labs over next five years 24 C
Slide 18: FY2016-9M2019 Total Outlets & FY2019 Development Targets
Business Updates FY2016-9M2019 Total Outlets & FY2019 Development Targets 129 118 9 2 FY2016 259 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 136 130 11 5 FY2017 283 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 143 128 14 7 FY2018 292 Outlets Clinical Labs POC
Slide 19: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 20: 9M 2019 Business & Financial Updates
9M 2019 Business & Financial Updates 20
Slide 21: New Clinical Labs & Clinic 9M 2019
Business Updates New Clinical Labs & Clinic 9M 2019 Clinical Lab, 2 Tangerang City, Banten 1 Prodia Health Care, 3 Clinical Lab, Prodia Senior Health Centre, 4 Surabaya, East Java Kemang, Jakarta Jatiwaringin, West Java Feb 2019 Mar 2019 Jun 2019 9M 2019 1 2 3 4 283 outlets 34 provinces 125 cities 1
Slide 22: 9M 2019 Revenue (Unaudited)
Business Updates 9M 2019 Revenue (Unaudited) Revenue (in IDR Billion) FY15-FY18 CAGR +10.1% g+7.2% g+10.9% 1,599.8 1,466.0 1,359.0 1,197.7 1,238.9 1,041.8 1,116.7 Visit and volume expansion continue to support double digit top line growth 2015 2016 2017 2018 9M 9M 9M 2017 2018 2019 22
Slide 23: Quarterly Revenue Trends (Unaudited)
Business Updates Quarterly Revenue Trends (Unaudited) Quarterly Revenue 2016 – 2019 (in IDR Billion) 500 Q3, 2019, 439.8 450 Q1 2019, Q2, 2019 399.5 399.6 2019 Quarterly revenue 400 illustrates seasonality 2018 in the business that is 350 2017 affected by different variables each quarter, 2016 inclu
Slide 24: FY2018 – 9M2019 New Test Developments
Business Updates FY2018 – 9M2019 New Test Developments Value-based Lab Testing Predictive, Preventive & Targeted Screening Diagnostic Therapy Pharmacogenomics 1. NIPT (ProSafe) 18. Jak2 Mutation 26. Jak 2 Mutation 36. Warfarin Indiv Test 2. Telomere Analysis 19. Kidney Stone Analysis 27. Mutation EG
Slide 25: Technology to increase Customer Satisfaction
Business Updates Technology to increase Customer Satisfaction • Launched e-Prodia, an Online Order & Result Platform, for easier registration, payment system, & results • Customers can choose type of testing & outlet via Online Order or Prodia Mobile Apps • Online Results are available for customers
Slide 26: Technology to increase Customer Satisfaction
Business Updates Technology to increase Customer Satisfaction Online Order via Prodia Mobile Online Results via Prodia Mobile 26
Slide 27: 9M 2019 Gross Profit & Net Income (Unaudited)
Financial Updates 9M 2019 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) Growth +7.3% Growth +11.8% Growth +7.7% Growth +13.6% 150.0 10.0% 121.0 722.3 98.9 106.5 9.8% 100.0 646.0 9.8% 9.6% 602.2 50.0 9.5% 9.5% 9.4% 57.8% 57.8% 58.3% - 9.2% 9M 2017 9M
Slide 28: 9M 2019 COGS & OPEX (Unaudited)
Financial Updates 9M 2019 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) CAGR 2015-2018 +8.7% g+7.1% g+9.8% CAGR 2015-2018 +8.3% g+6.2% g +10.7% 612.5 656.9 1,00050.0% 65.0% 565.0 770 511.0 114 516.6 713 101 470.7 800 676 60.0% 90 439.5 607 46 41 82 97 60045.0% 39 522 555 614 55
Slide 29: Financial Summary 9M 2019 (Unaudited)
Financial Updates Financial Summary 9M 2019 (Unaudited) (in IDR Bn) 9M 2019 9M 2018 Change Revenue 1,238.9 1,116.7 + 10.9% Gross Profit 722.3 646.0 + 11.8% EBIT 111.0 98.9 + 12.2% EBT 148.3 130.5 + 13.6% Net Income 121.0 106.5 + 13.6% EPS 129.0 113.6 + 13.6% EBITDA 188.8 166.0 + 13.7% EBITDA % 15.2%
Slide 30: Thank You
Thank You For more information : PT Prodia Widyahusada Tbk Investor.Relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221.3144182 ext. 3774, 3775 http://www.prodia.co.id
PT Prodia Widyahusada — 9M 2019 Earnings Presentation on 6ix